Quick Summary — SKIL scores higher on quality with 6.2/10 vs MYND's 4.7/10. MYND trades at $0.58 while SKIL trades at $7.97. Both analyzed daily using SEC EDGAR data across 13 institutional models.
SKIL scores higher with a 6.2/10 quality rating vs MYND's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
MYND currently trades at $0.58 while SKIL trades at $7.97. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily for both companies.
MYND earns a Quality of Company score of 4.7/10 compared to SKIL's 6.2/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
MYND carries a WARN value trap risk (57/100) while SKIL shows SAFE risk (18/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.
Both MYND and SKIL operate in Education & Training Services, which has 42 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare MYND vs SKIL differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.